What is it about?
In recent years, with the aging of society, the increase in arteriosclerosis-related diseases has become an obstacle to extending healthy life expectancy. One such disease, arteriosclerosis obliterans cause mainly decreased blood flow to the lower extremities, impairing walking, and in more severe cases, necrosis of the lower extremities, requiring amputation of the lower extremities. Standard endovascular and surgical treatments have not been satisfactory. Vascular regeneration therapy using mesenchymal stem cells is a promising treatment with proven efficacy, but the shortage of donors is a problem. To solve this problem, We focused on pigs and demonstrated for the first time in the world that transplantation therapy using neonatal porcine derived mesenchymal stem cells can improve murine hind limb ischemia.
Photo by Nick Fewings on Unsplash
Why is it important?
Recently, a case of xenotransplantation of a genetically modified porcine heart into a patient with severe chronic heart failure, which resulted in a short survival without hyperacute rejection, became a worldwide topic. In this study, we demonstrated that transplantation of neonatal porcine bone marrow-derived mesenchymal stem cells into a mouse model of lower limb ischemia improves blood flow in the lower limb. The cells can maintain cell proliferation and sterility better than adult porcine derived cells, and the short rearing period is less laborious and costly, making them a promising new donor.
Read the Original
This page is a summary of: Xenotransplantation of neonatal porcine bone marrow‐derived mesenchymal stem cells improves murine hind limb ischemia through lymphangiogenesis and angiogenesis, Xenotransplantation, May 2021, Wiley, DOI: 10.1111/xen.12693.
You can read the full text:
The following have contributed to this page